TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17380263
Drug: Needle-free injection
Normalized name: Stratis Needle-Free Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free injection system (Intraject) with various device configurations
Study: 8072258
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) treatment continued for 12 to 60 months
Study: 8072258
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) treatment with a dosage of up to 5.5 mg/kg/day
Study: 8072258
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) treatment with a dosage greater than 5.5 mg/kg/day
Study: 4886627
Drug: Treatment (nitrofurantoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (nitrofurantoin or ampicillin)
Study: 4886627
Drug: Reinfections post-treatment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reinfections post-treatment
Study: 31194213
Drug: Intracoronary (IC)
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary (IC) tirofiban administration
Study: 31194213
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) tirofiban administration
Study: 15456520
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 on day 1 and 8, and cisplatin (60 mg/m2 or 70 mg/m2 for older patients; 80 mg/m2 or 90 mg/m2 for younger patients) in 28-day cycles.
Study: 10806139
Drug: Terbutaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (1 mg four times a day)
Study: 10806139
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Terbutaline + Budesonide)
Study: 1281103
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens extract (160 mg t.d.) for 3 months
Study: 3912184
Drug: Bornaprolol (120,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprolol (120, 240 and 480 mg)
Study: 27886017
Drug: Physiotherapy twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy twice a week
Study: 14640990
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (5 microg/kg per day for 1 month and 10 microg/kg per day for 12-30 months)
Study: 10363394
Drug: Educational seminars
Normalized name: Semintra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational seminars on generic drugs and computer‐produced prescribing feedback (Intervention group)
Study: 1775612
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate administration
Study: 22234017
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg capsule orally 1 h before surgery
Study: 19237781
Drug: Ophthalmic viscosurgical
Normalized name: Viscoat Ophthalmic Viscosurgical Device Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic viscosurgical device (OVD) with balanced salt solution (BSS)
Study: 28526386
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/d)
Study: 11950430
Drug: Reduced-dose alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose alteplase plus abciximab
Study: 15353917
Drug: Reduced-dose alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose alteplase plus abciximab (within <2 hours)
Study: 11576058
Drug: Rocuronium (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (various doses)
Study: 9211571
Drug: Maprotiline 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline 100 mg daily
Study: 6124759
Drug: anti‐lymphocyte globulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti‐lymphocyte globulin, prednisolone, and azathioprine (3 mg/kg daily after 1 month)
Study: 6124759
Drug: placebo preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo preparations
Study: 29048958
Drug: Shade sails
Normalized name: shad scale pollen extract
DrugBank: Atriplex confertifolia pollen (DB10816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shade sails at treatment PRAs
Study: 29048958
Drug: Shade sails
Normalized name: shad scale pollen extract
DrugBank: Atriplex confertifolia pollen (DB10816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shade sails at treatment PRAs in Denver
Study: 24999799
Drug: Olmesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan plus diuretic
Study: 17037267
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least one dose vs. placebo
Study: 17037267
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least one dose vs. active control
Study: 12627416
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment at high dose
Study: 8526696
Drug: Oral quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinidine sulfate (300 mg)
Study: 3946169
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone
Study: 8526696
Drug: Oral digoxin/quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral digoxin/quinidine
Study: 28068613
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Activation Therapy for Depression (BATD)
Study: 26304767
Drug: Intact immediate‐release/extended‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact immediate‐release/extended‐release oxycodone/acetaminophen 15/650 mg
Study: 26304767
Drug: Intact immediate‐release/extended‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact immediate‐release/extended‐release oxycodone/acetaminophen 30/1,300 mg
Study: 19172130
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral rehydration solution and feeding advice without zinc)
Study: 9661646
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg/day for 4 days)
Study: 2643423
Drug: 38% fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% fat treatment diet (9% saturated fat, 15% polyunsaturated fat, 14% monounsaturated fat, 166 mg dietary cholesterol per day)
Study: 2643423
Drug: 39% fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 39% fat control diet (18% saturated fat, 5% polyunsaturated fat, 16% monounsaturated fat, 446 mg dietary cholesterol per day)
Study: 2643423
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment and control diets
Study: 1095962
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg SAMe i.v. or i.m. administered four times a day for 30 days
Study: 1095962
Drug: Equimolecular doses
Normalized name: Salicylic acid bimolecular ester
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equimolecular doses of L-methionine and ATP
Study: 30455321
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus background therapy of mycophenolate and steroids
Study: 25749542
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy plus famciclovir (antiviral treatment)
Study: 25749542
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (control group)
Study: 23429062
Drug: Higher body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher body mass index and less likely to report estrogen or aspirin use
Study: 19547811
Drug: bromazepam 3
Normalized name: bromazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromazepam 3 mg
Study: 16297442
Drug: Prescription-based counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription-based counseling and self-monitoring (MON)
Study: 9241008
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg/day on days 8-17 and 100 mg/day on days 18-20)
Study: 18415758
Drug: 3-l sulphate-free
Normalized name: 3-(L-MENTHOXY)-2-METHYLPROPANE-1,2-DIOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-l sulphate-free polyethylene glycol solution (SF-PEG)
Study: 18415758
Drug: 4-l polyethylene
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-l polyethylene glycol solution (PEG)
Study: 26672094
Drug: 75-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-g oral glucose tolerance test
Study: 7772935
Drug: 100-g oral
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-g oral glucose tolerance test
Study: 2181138
Drug: Antiemetic injections
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiemetic injections of prochlorperazine
Study: 31221693
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy + Community-based exercise (CBT+EXER) - concurrent over a 12-week period
Study: 1554179
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg haloperidol IM
Study: 1554179
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg droperidol IM
Study: 1554179
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg droperidol IV
Study: 4033866
Drug: Ethanol (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1.4 ml 100 proof vodka/kg body weight)
Study: 31368770
Drug: d-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-cycloserine (50 mg)
Study: 9296406
Drug: Ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.1 mg/kg to 4 mg intravenously)
Study: 8445378
Drug: Behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral group therapy (N = 30)
Study: 3296296
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily beclomethasone dipropionate (500 micrograms/day)
Study: 3296296
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times daily standard dose inhaler (400 micrograms/day)
Study: 20935398
Drug: AScVS (anti-scorpion
Approvals — FDA: no, EMA: no, PMDA: no
Description: AScVS (anti-scorpion venom serum) administered as an intravenous slow bolus, ranging from 40 to 100 ml depending on severity
Study: 20935398
Drug: Prazosin given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin given as 1 mg every 3 h
Study: 8450893
Drug: Amitriptyline (AM)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (AM) 50-75 mg
Study: 2876658
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg slow-release terbutaline sulphate tablets (Bricanyl Depot) given twice daily
Study: 2876658
Drug: Ordinary oral
Normalized name: Azo Urinary Pain Relief Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary oral beta 2-agonist treatment given three times daily
Study: 2876658
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg slow-release terbutaline sulphate tablets (Bricanyl Depot)
Study: 26271141
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) 50 mg every 4 weeks for 48 weeks
Study: 15620161
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration between the tibial tuberosity and the internal gastrocnemius muscle
Study: 11508654
Drug: Sumatriptan 20
Normalized name: sumatriptan 20 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 20 mg intranasally
Study: 9716275
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy for 2 weeks
Study: 9716275
Drug: Tryptophan therapy
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan therapy
Study: 12475511
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment (displaced position accepted, not rereduced)
Study: 10424315
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg once daily
Study: 29747269
Drug: Low-dose CEE
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CEE + progesterone
Study: 29747269
Drug: Standard-dose CEE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CEE + progesterone
Study: 29747269
Drug: Standard-dose CEE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CEE + dydrogesterone
Study: 29747269
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Low-dose CEE + progesterone, Standard-dose CEE + progesterone, Standard-dose CEE + dydrogesterone
Study: 22354104
Drug: Triple-injection US-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-injection US-guided AXB
Study: 22354104
Drug: Quadruple-injection US-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple-injection US-guided AXB
Study: 22354104
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (double, triple, quadruple injections)
Study: 12370684
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia (IVA) - continuous infusion of 30 mg of morphine and 180 mg ketorolac in 250 mL of normal saline at 5 mL/h.
Study: 10757583
Drug: Remifentanil 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 4 microg kg(‐1) + Propofol 2.5 mg kg(‐1)
Study: 1549538
Drug: Ofloxacin 600
Normalized name: ofloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 600 mg
Study: 2853934
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg three times daily
Study: 22914876
Drug: Prior brace
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior brace treatment for over 1 year (Group A)
Study: 22914876
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior treatment (Group B)
Study: 21420599
Drug: 0.25 mg/mL
Normalized name: thiram 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/mL diclofenac sodium
Study: 21420599
Drug: 0.25 mg/mL
Normalized name: thiram 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/mL combined diclofenac sodium and nuclear rotation
Study: 17534812
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (Group 1)
Study: 19864903
Drug: NaF solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF solution (positive control, 1,000 mg/kg F, pH 4.5)
Study: 15369510
Drug: G group
Normalized name: DIMETHICONE 10.2 mg in 1 mL TOPICAL SPRAY [KVG Group, Inc. FXP Cracked Heel Formula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: G group (genotypic group)
Study: 11443179
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg micronized estradiol‐17beta orally, twice daily for 14 days
Study: 7820215
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone replacement therapy
Study: 26205747
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (NSPT) in the form of scaling and root planing (SRP)
Study: 26205747
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no periodontal therapy)
Study: 23585306
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ibuprofen (400 mg ibuprofen/20 mL suspension)
Study: 21672969
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg i.v./6 weeks for 8 years
Study: 19682233
Drug: Pre-hospital high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital high-dose tirofiban
Study: 19682233
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no high-dose tirofiban/placebo)
Study: 14736293
Drug: Conceptual difficulty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conceptual difficulty in potential insight solution
Study: 3504454
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (0.5 mg) placed intracervically
Study: 20535638
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once daily (Group 1)
Study: 2090208
Drug: One single
Normalized name: Risperidone Single-Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose of 4 g piperacillin 30 minutes before surgery
Study: 2090208
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 4 g piperacillin (30 minutes before surgery, and 6 & 12 hours after surgery)
Study: 31897428
Drug: SYNT001 (FcRn-blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNT001 (FcRn-blocking monoclonal antibody)
Study: 28327503
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (140 mL; 800 mg nitrate/day)
Study: 26083948
Drug: Aspirin desensitization
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin desensitization (AD) with increasing doses of aspirin (60, 125, 325, and 625 mg) followed by 625 mg twice daily for 6 months
Study: 26366802
Drug: Aspirin desensitization
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin desensitization (AD)
Study: 23462833
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus Atorvastatin 10 mg
Study: 11996956
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg)
Study: 20183663
Drug: Solution‐Focused Thinking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution‐Focused Thinking
Study: 16395269
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose 100 mg
Study: 15312371
Drug: Postoperative TACE
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative TACE and thymosin alpha(1) (T(alpha1)) treatment (Group A)
Study: 9260798
Drug: Alendronate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (40 mg/day)
Study: 9260798
Drug: Aspirin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1, 300 mg/day)
Study: 29016880
Drug: Intranasal hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal hydrocodone ER
Study: 29016880
Drug: Intranasal hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal hydrocodone powder
Study: 29016880
Drug: Intranasal treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal treatments
Study: 29016880
Drug: Intact oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact oral hydrocodone ER
Study: 24535134
Drug: Laquinimod 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 0.6 mg once-daily
Study: 25458646
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitors
Study: 10838648
Drug: PATCH model
Normalized name: Model AA 2012 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PATCH model intervention (n=310)
Study: 23116485
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg)
Study: 3108064
Drug: Indomethacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (200 mg) administered 15 and 2 hours before testing
Study: 25209524
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) provided at discharge
Study: 24708748
Drug: Drug-negative patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-negative patients (84% opioids, 76% stimulants, 62% alcohol, 33% marijuana)
Study: 24708748
Drug: Drug-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-positive patients
Study: 21169896
Drug: Olanzapine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-10 mg daily)
Study: 21169896
Drug: Sertraline (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-100 mg daily)
Study: 17035872
Drug: iopamidol-370 (370
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol-370 (370 mgI/mL)
Study: 17035872
Drug: iodixanol-320 (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol-320 (320 mgI/mL)
Study: 23918282
Drug: Balloon treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon treatment
Study: 10696316
Drug: Injection into
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the intra‐Tenon's space (subconjunctival space) without making a conjunctival incision (116 eyes)
Study: 8540712
Drug: Cefodizime 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 0.5 g